John R. La Montagne Memorial Symposium on Pandemic Influenza Research Meeting Proceedings (2005) / Chapter Skim
Currently Skimming:
3 Morning Plenary Discussion, Day 1
3 Morning Plenary Discussion, Day 1
Pages 53-58
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 53... ...
First, in all the articles published on H5N1 and its potential, particularly its introduction into people, I have not seen any evidence of a rigorous study of the neuraminidase antibody concentration in a population that must have some N1 immunity. This is particularly important if we are facing inapparent infections and wondering about the sporadic occurrence of lethal or very severe diseases.
|
From page 54... ...
When the antigen dose quantity was higher, subcutaneous did better. More recently, in 1969 in the Canadian Journal of Public Health, Davies found that giving the same dose intradermally or subcutaneously with jet injectors for both routes produced a higher response intradermally, but the result was not significant.
|
From page 55... ...
, a country can issue a compulsory license during a public health emergency to allow other companies to manufacture the drug. I am interested at what point the panelists think the United States should evoke the TRIPS agreement to start producing its own Tamiflu.
|
From page 56... ...
Another important other aspect is the scalability of our use of these countermeasures. And at least with antivirals, the stockpile exists, and we have conceptualized the idea that we will deploy it under certain circumstances to obtain the biggest public health benefit for the amount of drug we have.
|
From page 57... ...
Unless we are prepared to spend money to create capacity that will not be used except during a crisis, we can develop all the technologies we want, but our actual ability to bring a stockpile to market is going to be limited. During the anthrax situation, the biggest problem many of us in the states faced concerned reagents for testing for bacillus anthracis -- they just did not exist.
|
From page 58... ...
DR. FINEBERG: As we begin to discuss research priorities in detail, we clearly have to consider the total preparedness strategy, including communication among scientists, across cultures and political boundaries, with the public at large, and with policymakers.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.